Figure 1
From: Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Comparison of number of trials of symptomatic cognitive-enhancing agents and of disease-modifying agents in the 2002 through 2012 period.
Figure 1 | Alzheimer's Research & Therapy